The pittsburgh cervical cancer screening model a risk assessment tool

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 5, 2010, Pages 744-750

  Austin, R Marshall ^a   Onisko, Agnieszka ^a   Druzdzel, Marek J ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ARTICLE; EARLY DIAGNOSIS; FEMALE; HUMAN; METHODOLOGY; PAPILLOMAVIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADENOCARCINOMA; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77952019594     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943. (Pubitemid 46740303)
2. Lee KR, Ashfaq R, Birdsong GG, Corkill ME, Mcintosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol. 1997;90(2):278-284.
3. Bishop JW, Bigner SH, Colgan TJ, et al. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears including initial biopsy results. Acta Cytol. 1998;42(1):189-197.
4. Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ. The AutoPap System for primary screening in cervical cytology: comparing the results of a prospective, intended-use study with routine manual practice. Acta Cytol. 1998;42(1):214-220.
5. Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid-based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007;335(7609):31.
6. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299. (Pubitemid 32219816)
7. Zahn CM. Human papillomavirus DNA testing as an adjunct in primary screening: is it prime time? Obstet Gynecol. 2004;103(4):617-618.
8. Austin RM, Onisko A, Druzdzel M. The Pittsburgh Cervical Cancer Screening Model. Cancer Cytopathol. 2008;14S:345A.
9. Austin RM, Onisko A, Druzdzel M. Bayesian network model analysis as a quality control and risk assessment tool in cervical cancer screening: biennial meeting of ASCCP. J Lower Genital Tract Dis. 2008;12:160-161A.
10. ACS. 2006 US Census Bureau American Community Survey (ACS). http:// www.census.gov/acs/www/. Accessed June 23, 2009.
11. Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol. 2009;114(3):383-389.
12. Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of more than 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol. 2009;115(2):257-261.
13. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med. 2008;132(12):1874-1881.
14. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol. 2007;107(2):231-235.
15. Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer Cytopathol. 2008;114(4):242-248.
16. Armah H, Austin RM, Dabbs D, Zhao C. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice. Arch Pathol Lab Med. 2009;133(9):1426-1430.
17. Pearl J. Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. San Mateo, California: Morgan Kaufmann Publishers Inc; 1988.
18. Friedman, N., Murphy, K., Russell, S. Learning the structure of dynamic probabilistic networks. In: Proceedings of Fourteenth Conference on Uncertainty in Artificial Intelligence; July 24-26, 1998; Madison, WI. San Mateo, CA: Morgan Kaufmann; 1998:139-147.
19. Harmanec D, Leong TY, Sundaresh S, et al. Decision analytic approach to severe head injury management. In: Proceedings of the 1999 AMIA Annual Fall Symposium; Washington, DC: American Medical Informatics Association; 1999: 271-275.
20. Leong TY. Multiple perspective dynamic decision making. Artif Intell. 1998;105(1-2):209-261.
21. Xiang Y, Poh KL. Time-critical dynamic decision modeling in medicine. Comput Biol Med. 2002;32(2):85-97. (Pubitemid 34203738)
22. Galan SF, Aguado F, Diez F, Mira J, NasoNet, modeling the spread of nasopharyngeal cancer with networks of probabilistic events in discrete time. Artif Intell Med. 2002;25(3):247-264.
23. van Gerven MAJ, Taal BG, Lucas PJF. Dynamic Bayesian networks as prognostic models for clinical patient management. J. Biomed Inform. 2008;41(4): 515-529.
24. Yao XQ, Zhu H, She ZS. A dynamic Bayesian network approach to protein secondary structure prediction. BMC Bioinformatics. 2008;9:49.
25. Klammer AA, Reynolds SM, Bilmes JA, MacCoss MJ, Noble WS. Modeling peptide fragmentation with dynamic Bayesian networks for peptide identification. Bioinformatics. 2008;24(13):i348-i356.
26. Ferrazzi F, Sebastiani P, Isaac S, et al. Dynamic Bayesian networks in modelling cellular systems: a critical appraisal on simulated data. In: CBMS 2006: The 19th IEEE International Symposium on Computer-Based Medical Systems; June 22-23, 2006; Salt Lake City, UT. New York, NY: IEEE Computer Society; 2006:544-549.
27. Zou M, Conzen SZ. A new dynamic Bayesian network (DBN) approach for identifying gene regulatory networks from time course microarray data. Bioinformatics. 2005;21(1):71-79.
28. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
29. Kirkwood B, Sterne J. Essentials of Medical Statistics. Malden, MA: Blackwell Science; 2003.
30. Muhlberger N, Sroczynski G, Esteban E, et al. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German federal Ministry of Health. Int J Technol Assess Health Care. 2008;24(2): 184-192.
31. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308-320.
32. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5:11.
33. Siebert U, Sroczynski G, Hillemanns P, et al. German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health. 2006;16(2):185-192.
34. Bidus MA, Maxwell GL, Kulasingam S, et al. Cost-effectiveness analysisof liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol. 2006;107(5):997-1005.
35. Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. Eur J Health Econ. 2005;5(1):30-37.
36. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158-1171.
37. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol. 2000;78(2):97-105.
38. Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma ofthe cervix diagnosed as a consequence ofcytologic screening. Acta Cytol. 2003;47(2):167-171.
39. Miller AB. The (in)efficiencyofcervical screening in Europe. Eur J Cancer. 2002;38(3):321-326.
40. Ronco G, van Ballegooijen M, Becker N, et al., Process performance of cervical screening programmes in Europe, Eur J Cancer. 2009;45(15):2659-2670.
41. Strander B, Andersson-Ellström A, Milsom I, Spartén P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335(7629):1077.
42. Miller MG, Sung HY, Sawaya GF, Kearney KA, Kinney W, Hiatt RA. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol. 2003;101(1):29-37.
43. Belinson J, Quao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: a cross sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2004;83(2):439-444.
44. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
45. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682.
46. Cuzick J, Clavel C, Petry KU, et al. Overview of European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-1101.
47. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol. 2009;114(2):360-364.